Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News 4D Molecular Therapeutics Inc FDMT

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular... see more

Recent & Breaking News (NDAQ:FDMT)

4DMT to Participate in the 2024 Cantor Global Healthcare Conference

GlobeNewswire September 3, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

Accesswire August 28, 2024

4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024

GlobeNewswire August 27, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

PR Newswire August 26, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

Accesswire August 22, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

Accesswire August 21, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

Accesswire August 19, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

PR Newswire August 17, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

Accesswire August 15, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

Accesswire August 13, 2024

4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

GlobeNewswire August 12, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

Accesswire August 11, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

PR Newswire August 9, 2024

4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights

GlobeNewswire August 8, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

Accesswire August 7, 2024

4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board

GlobeNewswire August 5, 2024

FDMT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 4D Molecular Therapeutics, Inc. and Encourages Clients to Contact the Firm!

Accesswire August 2, 2024

FDMT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 4D Molecular Therapeutics, Inc. and Encourages Shareholders to Contact the Firm Today!

Accesswire August 1, 2024

FDMT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 4D Molecular Therapeutics, Inc. and Encourages Shareholders to Contact the Firm Today!

Accesswire July 31, 2024

4D Molecular Therapeutics, Inc. (FDMT) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates

Accesswire July 30, 2024